Industry Overview

Transcription

1

2 Biotech Directory Industry Overview SURVEY & RANKING METHODOLOGY BioSpectrum conducted this survey jointly with the Association of Biotechnology Led Enterprises (ABLE). BioSpectrum and ABLE have jointly been doing this exercise since A detailed questionnaire (survey form) was sent to over 150 companies to capture the needed information for the analysis. This was done during April-May Companies shared information with us to the extent it was possible by them about their companies and the industry. The revenues considered for the analysis are biotech products sales and service figures. In several cases, where revenue figures were not available estimates were arrived talking to industry experts. These are denoted (*) as BioSpectrum estimates. This year in the list of Top 20 biotech companies, services companies in the drug discovery space have been taken into account, while diagnostics companies have not been considered. An overall listing of companies (Page 110 & 112) by revenue has been done for your reference including diagnostic companies. Biotech suppliers revenues are not considered as part of the biotech definition. BioPharma included products made by fermentation/ animal cell culture (not animal extracts) and plant cell culture (not plant extracts). The BioAgri segment analysis has included only the GM seeds and molecular markers and related products. So, the hybrid seeds business is not a part of the agri-business sales values. For all the ranking purposes, we have taken the biotech business only into consideration. Wherever TURNOVER is mentioned it means, sales turnover from biotech. Therefore, turnover wherever mentioned is not necessarily the total sales turnover of the company. A CyberMedia Publication biospectrumindia.com June 2010 BIOSPECTRUM 19

3 Industry Biotech Directory Overview India biotech recovers Size $3 bn Grows17% Registers Rs 14,199 cr INDIA BIOTECH INDUSTRY BioPharma BioServices Total BioAgri BioIndustrial BioInformatics Total Total Revenue Total-6521 Total Total Total FY Total Total *All figures in Rs. Crore unless indicated otherwise 20 BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication

4 Industry Biotech Directory Overview BioAgri grows at 37% BioServices follows at28% In dollar terms, the industry crossed $3 billion in FY growing 23% over a flat growth of FY Exports accounted for 53% share in the overall revenue and registered a growth of 5% over FY Domestic business claimed 47% share in the overall revenue and registered a growth of 34% over FY Biotech Industry Exports vs Domestic Segment Exports Domestic Total % share Exports % share Domestic Biopharma BioServices BioAgri BioIndustrial BioInformatics Total Biotech Industry Exports vs Domestic Segment Exports Domestic Total % share Exports % share Domestic Biopharma BioServices BioAgri BioIndustrial BioInformatics Total *All figures in Rs. Crore unless indicated otherwise A CyberMedia Publication biospectrumindia.com June 2010 BIOSPECTRUM 21

5 Industry Biotech Directory Overview Biotech Industry Segment Revenue % Share BioPharma BioServices BioAgri BioIndustrial BioInformatics % Share 2010 Total revenue Rs 14,199 Crore % Share 2009 Total revenue Rs 12,137 Crore Biocon back to No. 1 slot Highlights Biotech Industry Segment Revenue % Change Revenue share % change over Revenue share % change over Top 20 companies contributed 52% of the total revenue. These companies grew at an average growth rate of over 22% while the industry growth rate stood at 17% in FY Serum Institute of India slipped to No. 2 on account of loss of some key contracts. Shantha Biotech is the only Top 20 revenue company to have showcased a growth over 30% percent. Total revenues of Top 20 homegrown companies have grown by 25% over FY Fastest growing 20 companies contributed 20% of the overall industry revenue of Rs crore. These have grown at an average rate of over 150%. The pack of fastest growing companies in the region is led by CROs, which are growing from a very small base of less than Rs 30 crore. The fastest growing 20 companies in the region are all below Rs 150 crore with the exception of Shantha Biotech at Rs crore Biopharma BioServices BioAgri BioIndustrial BioInformatics Segment % Change Over % Change Over Biopharma BioServices BioAgri BioIndustrial BioInformatics Total *All figures in Rs. Crore unless indicated otherwise 24 BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication

6 Top 20 Biotech Companies by Revenue ( ) Industry Biotech Directory Overview Revenue Rank (Revenue (Revenue (Revenue % Change % Change Over Over Biocon Serum Institute of India* Panacea Biotec Nuziveedu Seeds Reliance Life Sciences* Quintiles* Rasi Seeds NovoNordisk* Shantha Biotech Mahyco Indian Immunologicals Bharat Biotech Novozymes South Asia* Monsanto* Syngene International Jubilant Organosys Eli Lilly Bharat Serums Haffkine Biopharma Siro Clinpharm Top 20 Biotech Companies by Growth ( ) Revenue Rank (Revenue (Revenue (Revenue % Change Over % Change Over Stempeutics Lambda Therapeutic Research* Max Neeman International Concord Biotech Krishidhan Seeds Aventis Pharma Maps (India)* Nath Seeds Anthem Biosciences Suven Life Sciences Cadila Healthcare Dr Reddy s Laboratories Mahyco* GlaxoSmithKline Wyeth* Advanced Enzymes Ankur Seeds Shantha Biotech JK Agrigenetics* ABL Biotechnologies * BioSpectrum estimates All figures in Rs. Crore unless indicated otherwise A CyberMedia Publication biospectrumindia.com June 2010 BIOSPECTRUM 25

7 Industry Biotech Directory Overview It was the Year of Recovery for the industry marked by consolidation, collaborations and a spate of deals between pharma and biotechs. The second half of 2009 saw most companies, primarily biopharma companies, posting healthier topline and margins. The Shantha Biotech-Sanofi Pasteur deal in 2009 became a defining point in the industry with Shantha selling-out at eight times its valuation of Rs 3,475 crore ($770 million). The trend of MNCs scouting for and acquiring domestic players with a strong foothold in the market picked up steam after this. Western cluster continues to dominate India s biotech industry with 46% share in the overall revenues of Rs 14,199 crore. The 137 companies in the region between themselves clocked Rs 6,631 crore in FY increasing the region s share in the overall revenues by 3 % over FY , thus gaining a lead of 6 % over South, its close competitor for the top slot. The Indian BioPharma market comprising primarily of vaccines, therapeutic drugs, insulin, animal biologicals, statins and diagnostics in , continued to grab the largest share of the total biotech industry revenues of over Rs 14,199 crore. It contributed Rs 8829 crore, accounting for 62% revenue share. In terms of PE funding in life sciences, in an estimated $200 million was invested in the India biotech industry with 40% of this being pumped into the BioPharma segment. Within BioPharma vaccines, diagnostics and medical devices have been the lucrative sectors for most of the Indian PE investors. Investors are also bullish about mabs space. The government of India through Department of Biotechnology (DBT) allocated Rs 902 crore for various projects in This allocation for is Rs 1,200 crore. The collaborations and public-private partnerships in the biotech industry are on the rise. The initiatives from DBT Small Business Innovation Research Initiative (SBIRI), and the Bill & Melinda Gates Foundation are some of the examples of collaborations between government and industry. DBT has also tied up with UK-based Wellcome Trust to enhance cutting-edge biomedical research in India. The trust has allocated 30 million pounds for a period of five years to fund R&D research in India. Top 20 Homegrown Biotech Companies by Revenue ( ) Revenue Rank (Revenue (Revenue 28 BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication (Revenue % Change Over % Change Over Biocon Serum Institute of India* Panacea Biotec Nuziveedu Seeds Reliance Life Sciences* Rasi Seeds Shantha Biotech Indian Immunologicals Bharat Biotech Syngene International Jubilant Organosys Bharat Serums Haffkine Biopharma Siro Clinpharm Cadila Healthcare Lambda Therapeutic Research* Krishidhan Seeds Intervet India* Advanced Enzymes Intas Biopharma * BioSpectrum estimates All figures in Rs. Crore unless indicated otherwise

8 Biotech BioCluster Directory BioSpectrum ABLE 1 Biotech Industry Survey 2010 position The region has improved its lead over South by 6% Mumbai outpaces Bangalore, becomes India s Top Biotech City West retains No Western cluster continues to dominate India s biotech industry with 46 percent share in the overall revenues of Rs 14,199 crore. The 137 companies in the region between themselves clocked Rs 6,631 crore in FY increasing the region s share in the overall revenues by 3 percent over FY , thus gaining a lead of 6 percent over South, its close competitor for the top slot. Not just that, this year, Mumbai outpaced Bangalore to become India s Top Biotech City with a small margin of about Rs 200 crore in terms of revenue. Besides, Gujarat s share in the total revenue has grown by almost 50 percent as compared to its revenues of Rs 755 crore in In Maharashtra, Pune s contribution went down as the leading company of the region Serum Institute of India suffered contract set backs. So, has South region s position visa-via West worsened since last year? Not really. Given the policy and infrastructure push the situation next year could even see a dramatic shift. South continues to remain India s largest Biotech cluster in terms of the number of companies. In , it added another 9 companies highest in the country. The region has 172 biotech companies (West has 137 companies), which churned out Rs crore in revenues in FY making up 39 percent of the overall revenues. In the South region, Karnataka state government has proposed to set up five new biotech parks and has invested Rs 1,100 crore towards new initiatives in Another biotech hub Andhra Pradesh is also setting up a MedTech Valley, a world-class Top Companies in West Top Companies in South Top Companies in North (Revenue in Rs Cr) (Revenue (Revenue in Rs Cr) % Share in Region % Share in Region % Share in Region % Share of Total Biotech Serum Institute of India* Reliance Life Sciences* Quintiles* Mahyco Monsanto* Bharat Serums Haffkine Biopharma Siro Clinpharm Cadila Healthcare Lambda Therapeutic Research* Ajeet Seeds* Top 10 West Total West % Share of Total Biotech Biocon Nuziveedu Seeds Rasi Seeds NovoNordisk* Shantha Biotech Indian Immunologicals Bharat Biotech Novozymes South Asia Syngene International Ecron Acunova Top 10 South Total South % Share of Total Biotech Panacea Biotec Jubilant Organosys Eli Lilly Top 3 North Total North *BioSpectrum estimates All figures in Rs. Crore unless indicated otherwise 30 BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication

9 Biotech BioCluster Directory Top Biotech Clusters & Cities ( ) Biotech Revenue Cluster Trend ( ) West South North Total cluster for manufacturing medical devices and equipment near Genome Valley at Shameerpet in Hyderabad. The state government will provide 1,200 acres of land for the project. The project will be executed via a public-private partnership model. Kerala has also taken steps to jump on the biotech bandwagon. Kerala State Industrial Development Corp (KSIDC) has announced that it will set up a state-of-the-art life science park at Thiruvananthapuram at an estimated cost of Rs 300 crore. The project that will come up in 260 acres at Thonnakkal, would be developed under public-private partnership model. The park will house an incubation center, a technology development center, biotechnology compa- Top 10 companies in the West have 43% share in the region. Serum Institute of India (Rs 850 crore), the region s No 1 company makes up for about 13% of the region s revenue and contributes 6% to the overall industry revenue BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication

10 Biotech BioCluster Directory nies, drug discovery companies, pure play firms and also contract research outsourcing units. Looking ahead, year will see some shifts, specializations and emergence of clear patterns. During this period many of the mega initiatives are likely to take off and have the potential to be a leap of sorts that can build a virtuous cycle for the region. NCR at No 4 The Northern biocluster National Capital Region (NCR) has the Top 3 companies contributing 56 percent of the revenues and about 15 percent of the overall industry revenue. This cluster is better known for its research institutes and of course, government bodies. More recently, the development of 200 acre Health Biotech Science Cluster (HBSC) at Faridabad is underway. A multidisciplinary approach to education and research, this Biotech cluster would comprise Translational Health Science & Technology Institute (THSTI), Regional Center for Biotechnology (RCB) Center for Vaccinology, Molecular Medicine Center, Center for Diagnostics, Biotech Park,), Center for Health Science Technology, Center for Platform Technologies, UNESCO Center, Incubator and a Center for Animal Model for Clinical Advances. As a first step, a temporary THSTI lab was recently inaugurated at Gurgaon. This would be shifted to the main site at Faridabad in two-three years after the infrastructure is ready. Besides, there is the biotech park at Lucknow offering a very good platform for the small and medium biotech companies to do research, collaborate and expand their business. The Biotech Parks at three locations Sitapura-Jaipur and Chopanki, Bhiwadi (Alwar), and Borandi, Rajasthan have been initiated by Rajasthan State industrial Development & Investment Corporation (RIICO). Then, there is the proposed biocluster at Mohali (Punjab), upcoming biotech park at Chandigarh (Punjab) and another one at Nalagarh in Himachal Pradesh all this is expected to provide the much needed boost to the biotech companies in the North region. West is also base for top bioagri companies such as Monsanto, Mahyco and Ajeet Seeds. MNCs like GlaxoSmithKline, Roche, Aventis Pharma, Wyeth, Quintiles are also headquartered in the region. Four of India s top 10 services companies (CROs) are also based out of West, including the No 1 CRO in the Indian industry Quintiles India (Rs 375 crore) *All figures in Rs. Crore unless indicated otherwise A CyberMedia Publication biospectrumindia.com June 2010 BIOSPECTRUM 33

11 Segment Biotech Directory Overview BioPharma to grow over 10% for next 5 years BioPharma clocks Rs 8,829 crore in revenues It accounted for 62% of the total revenue and grew by 12% over FY The Top 20 BioPharma companies contributed close to Rs 6000 crore The Indian BioPharma market comprising primarily of vaccines, therapeutic drugs, insulin, animal biologicals, statins and diagnostics in , continued to grab the largest share of the total biotech industry revenues of over Rs 14,199 crore. It contributed Rs 8,829 crore, accounting for 62 percent market share. Vaccines had the largest pie with an estimated sales of Rs 2,180 crore over last year s figure of Rs 2,000 crore. The vaccine segment human as well as animal vaccines accounted for percent of the total BioPharma market. Total estimated sales from the human vaccine business stood at Rs 1,750 crore over the figure of Rs 1,550 crore. Domestic sales of human vaccines just about crossed Rs 1,000 crore. In FY this figure stood at Rs 900 crore. Export sales is estimated to have generated Rs 750 crore, as compared to Rs 650 crore in FY Animal Vaccines registered a marginal decline Top 20 BioPharma Companies by Revenue ( ) Revenue Rank (Revenue (Revenue % Change Over Biocon Serum Institute of India* Panacea Biotec Reliance Life Sciences* NovoNordisk* Shantha Biotech Indian Immunologicals Bharat Biotech Eli Lilly Bharat Serums Haffkine Biopharma Cadila Healthcare GlaxoSmithKline Intervet India Intas Biopharma Themis Medicare Concord Biotech Venkateshwara Hatcheries* Aventis Pharma Dr Reddy s Laboratories * BioSpectrum estimates 36 BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication All figures in Rs. Crore unless indicated otherwise

12 Segment Biotech Directory Overview with sales of Rs 430 crore over last year s figure of Rs 450 crore. In animal vaccines, poultry vaccines clocked Rs 220 crore, cattle and sheep vaccines registered Rs 210 crore. The vaccine market will continue to drive the growth of the biopharma segment growing in the range of percent in the next 5 years. The factors that will drive this include education and awareness about disease prevention, increase in disposable income and participation by government. The vaccine market will continue to drive the growth of the biopharma segment growing in the range of 10-13% in the next 5 years The market will clearly shift to combination vaccines such as Pentavalent vaccines. Domestic players such as Bharat Biotech and Shantha Biotech have already received massive orders from the Government of India for immunization programmes in Himachal Pradesh, Kerala, Tamil Nadu, Jammu and Kashmir and Karnataka. There is going to be a change from largely whole-cell pertusis -based combos to acellular-based combos in the coming years. Newer vaccines like Pneumo conj, Meninge Conj and HPV would drive the market growth in paediatric and adolescent segment, while Flu will continue to be a big driver in the adult market segment. A noteworthy product launched during was Shantha s Shanchol India s first oral vaccine to protect against cholera. Shanchol is a bivalent inactivatedwhole-cell oral cholera vaccine developed by Shantha in collaboration with the International Vaccine Institute (IVI), Seoul, Korea. Driven by a rise in chronic diseases and investments in the healthcare infrastructure, diagnostics and therapeutics business also had a positive impact on the industry. The diagnostic market is estimated to be at Rs 2,000 crore with molecular diagnostic market share at $300 million in FY This accounts for percent share of the total BioPharma market. A highly competitive segment, the market currently is growing at percent with a 50:50 revenue share split between MNCs and homegrown companies. Major MNC companies in the diagnostic market include Roche, Siemens (which has acquired Bayer Diagnostics) and Abbott while homegrown names in the top league include Tulip Group, Transasia Biomedicals, RFCL (Diagnova), Span Diagnostics and Trivitron. This growth is driven from the gradual acceptance of the concept of preventive and personalized medicine. The therapeutics market claimed 15 percent of market share in FY with the cancer therapeutics sales clocking Rs 311 crore. Companies in the segment are now moving towards novel targeted therapies and supportive care products. Cancer therapeutics is a lucrative business for many Indian companies because of high unmet needs, high prices of innovator drugs, increase of awareness and affordability. These homegrown players will play a pivotal role in reducing the price points of important cancer drugs. The market size of Oral Diabetes Drugs is estimated to be Rs 1,550 crore and market size of Insulin (including analogs) is approximately Rs 612 crore. The large market size is reflective of India emerging as the diabetes capital of the world. Between 1995 and 2005 the number of diabetic patients doubled from 20 million to 40 million and this is projected to grow to 70 million patients by In Insulin (including Analog) segment, Novo Nordisk is the market leader with over 50 percent market share while Eli Lilly has 22 percent market share. Analogs which currently contribute 27 percent in value (8 percent in volume) are the fastest growing segment (with CAGR of 32 percent) in value. Within insulin market, novel delivery devices would be the growth drivers in the coming years. Biogenerics segment in the near term will be a key growth driver for Indian players especially with the US set to establish a biogenerics (biosimilars) pathway by In India, Erythropoietin (EPO) clocked a sales of Rs 10 lakh ($22,000), c-gsf Rs 5 lakh ($11000), interferon Rs 10 lakh $22000 and streptokinase Rs 7 lakh ($16000). These products are been sold at price discounts of upto almost 85 percent of its innovator drug thus making them affordable to the masses. Currently, Dr Reddy s Labs, Ranbaxy, Biocon, Shantha Biotechnics and Intas Biopharmaceuticals are actively involved in the space. There are around 25 Indian players with over 50 products already being sold in the Indian market and some being sold in the unregulated markets as well. Other prominent companies that have started initiatives in the field include Glenmark, Cipla and Lupin Pharma. Last year, Cipla entered into a 50:50 joint venture (JV) with a Chinese company for biosimilars. The JV would be called Biomab and Cipla is likely to bring out Biomab s first product later this year. 38 BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication

13 Segment Biotech Directory Overview CROs take the growth highway BioServices registers 28% growth with revenue of Rs 2,639 crore Top 10 CROs make up 60% of the total segment revenue BioServices segment registered a growth of 28 percent in over last year s total segment revenue of Rs 2,062 crore. The 3 percent drop in growth from a 31 percent of was primarily due the currency fluctuations in FY Exports continue to dominate this segment accounting for over 90 percent of the total revenues. In this segment, accounting for 19 percent of overall revenue, companies such as Lambda Therapeutic Research, MaxNeeman and Anthem Biosciences have done exceedingly well in FY with Lambda and MaxNeeman growing well over 100 percent and Anthem Biosciences at over 60 percent. The Top 10 CROs make up 60 percent of the total segment revenue of Rs 2,639 crore. In the last three-to-five years, many companies have set up contract research and clinical research services operations in India. Considering the potential opportunity and fast clip market growth, the number of companies in this segment will continue to grow faster than the industry average in the next two years as well. The segment is growing on account of the growing requirements of the multinational companies that are looking at India as an outsourcing destination with high-skill, low cost advantage. Besides, due to business model evolutions driven by market forces, even the domestic companies are outsourcing various portions of the drug discovery chain. However, the competition in the segment is growing to be intense impacting bottomlines adversely. The fact that all new companies are now born global is adding to this competition. SIRO Clinpharm having presence in India, Western & Central Eastern Europe, and US has now entered into an alliance with Dream- CIS Inc., a leading CRO based out of Top 10 Services Companies by Revenue ( ) Rank (Revenue (Revenue % Change Over Quintiles India* Syngene International Jubilant Organosys Siro Clinpharm Lambda Therapeutic research* 6 Veeda Clinpharm Ecron Acunova 97 8 Vimta Labs Anthem Biosciences Max Neeman International * BioSpectrum estimates All figures in Rs. Crore unless indicated otherwise Seoul in South Korea. The company has also signed an agreement with Virginia Contract Research Organization (VCRO), a Taiwan-based CRO to offer a range of services to Taiwan companies. And, it is not just Asia Pacific market that the company is looking at. SIRO is expanding operations in the developed markets like USA and Europe as well. It has entered an alliance with Advanced Clinical Trial Solutions (ACT Solutions), Flemington, NJ, USA. Syngene International, a subsidiary of Biocon Group, has partnered with Sapient Discovery, a US-based biotechnology company. Both the companies intend to provide a highly integrated platform for structurebased drug discovery. It also signed a pact with another US company, Endo Pharma, to jointly discover and develop novel biological drug molecules to fight cancer. Bangalore-based Ecron Acunova has tied-up with a Japanese CRO and expects this alliance to trigger a trend and set off clinical trials between India and Japan in the next two-to-three years. Japan is the second biggest pharma market after the US. This apart, the Indo-German clinical research major with its established presence in India and Europe is scouting for more market share in clinical research in these countries and other parts of the globe. Veeda Clinical Research, which has completed five years of existence in January 2010, has opened its office in South East Asia by signing a collaborative agreement with the Malaysian Ministry Health to open a Phase I and Early Clinical Development Unit in the Ampang Hospital in Kuala Lumpur. India services industry is, decidedly, set to take the collaboration growth highway. 40 BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication

14 Segment Biotech Directory Overview A fast clip growth for BioAgri Agri biotech grew at 37% in FY There are over 30 companies marketing Bt cotton seeds in India The segment will grow at an average of 26% in the next 5 years Agri biotech is the third largest contributor to Indian biotech industry in FY with a total segment turnover of Rs 1,936 crore, accounting for almost 14 percent of the total biotech revenues. Registering a growth of 37 percent over last year, BioAgri emerged the industry s fastest growing segment. The fact that BioServices segment dominated by exports faced minor setbacks on account of currency fluctuations helped BioAgri gain lead. In FY BioServices with a growth of 31 percent was the fastest growing industry segment. India is the fourth largest country in the world with almost 8.4 million hectares of area under Bt cotton. On Region North West Central South Rank 2010 Production 600 kg per hectare 516 kg per hectare 472 kg per hectare 595 kg per hectare one side the area under Bt cotton has been on increasing, on the other side the prices for Bt seeds packets has been slightly on decline. This decline is because of government s intervention and more companies launching different technologies for producing Bt seeds. The number of companies selling Bt cotton seeds in India has increased dramatically over the last eight years since the first commercialization in Today, there are over 30 companies marketing Bt cotton seeds in the country. Nuziveedu Seeds is the largest seller of Bt cotton seeds. The company sold 70 lakh packets generating Rs crore in revenues. Rasi Seeds is the second largest contributor with Rs crore in sales. Nuziveedu has 25 percent of the market share while Rasi Seeds is close second with 19 percent market share. Other significant players include Ajeet Seeds, Ankur Seeds selling lakh packets each in FY Top 10 Agri Companies by Revenue ( ) (Revenue (Revenue % Change Over Nuziveedu Seeds Rasi Seeds Mahyco Monsanto* Krishidhan Seeds Ankur Seeds Ajeet Seeds* Nath Seeds JK Agrigenetics* Bayer CropScience* 22.5 * BioSpectrum estimates All figures in Rs. Crore unless indicated otherwise A total of 280 lakh packets of seeds containing 450 grams were sold in 2009, approximately 87 percent being Bollgard II and 13 percent bollgard I. An additional 20 lakh packets of spurious seeds were estimated to have been sold illegally to the farmers mainly in Gujarat state. While in most of the regions, the Bollgard I and Bollgard II cotton seeds were priced at Rs 650 and Rs 750 respectively. In North (mainly Punjab, Haryana and Rajasthan), the pricing was kept at Rs 759 for Bollgard I and Rs 925 for Bollgard II. The Bollgard Bt cotton seeds were sold in nine states-andhra Pradesh, Tamil Nadu, Karnataka, Gujarat, Madhya Pradesh, Maharashtra, Haryana, Punjab, and Rajasthan. Maharashtra leads as the largest selling state with almost 90 lakh packets sold in the region followed by the South (75 lakh packets) and North (45 lakh packets). The northern market is mainly held by Shriram Bioseeds. A region wise split shows that the Northern region of India recorded maximum production of Bt cotton. An important event of 2009 was the approval of MLS 9124, developed indigenously by Metahelix Life Sciences. The product has a synthetic cry 1C gene. The other development was the release of two cotton hybrids namely MH 5124 and MH 5174 expressing the synthetic cry 1C gene (MLS 9124). Notes: *Monsanto royalty has not been taken into account as segment revenue 42 BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication

15 Segment Biotech Directory Overview BioIndustrial to grow over 15% for next 5 years BioIndustrial grew 16% in FY % of the industrial enzyme domestic demand is imported The BioIndustrial market mainly comprising industrial enzymes is estimated to be Rs 564 crore in the year as against Rs 478 crore in The segment grew 16 percent in FY Though the overall enzyme consumption figures of India are comparatively low with respect to other countries and percent of domestic demand is imported, the segment on an average has been growing over 15 percent in the last five years. In India, the industrial enzyme consumption is predominantly in the detergents market (40 percent), followed by the starch market (25 percent). The other important segments are food and feed, textiles, leather, pulp and paper. In recent years, enzymes have found numerous applications in the food, pharmaceutical, diagnostic and chemical processing industries. The trend for their application in almost every sector Top 3 BioIndustrial Companies by Revenue ( ) Rank Novozymes South Asia* is on increase. The leading players in this segment include Novozymes which has over 50 percent market share followed by Advanced Enzyme Technologies holding percent market share. Other important players are Maps, Genecor, Lumis and Kerry Biosciences. Besides, a new entrant Anthem Cellutions, a part of Anthem Biosciences group has gained significant market share over a short period of time. Apart from focusing on the local market, companies like Advanced Enzyme Technologies are looking at (Revenue (Revenue % Change Over Advanced Enzymes *BioSpectrum estimates All figures in Rs. Crore unless indicated otherwise other markets such as China. Considering the potential opportunity in the other markets Advanced Enzyme has registered good growth in its export sales. The Indian companies are reporting a good growth, a lot of R&D is happening in these companies and new applications are being explored. Indian companies are looking at technologies from Europe, China and Australia. However, with respect to global enzyme industry India still needs to do a lot of catching up. BioInformatics grows at sluggish pace Top 3 BioInformatics Companies by Revenue ( ) Rank (Revenue (Revenue % Change Over Ocimum Biosolutions Strand Life Sciences *All figures in Rs. Crore unless indicated otherwise The smallest segment of the Industry, BioInformatics which has just about 2 percent segment share in the overall industry, has been sluggish in FY It registered a 5 percent growth over , clocking Rs 231 crore in revenues last year as compared to Rs 220 crore in FY , when it recorded a growth of 16 percent. The pure-play BioInformatics companies in India include Strand Genomics, Ocimum Biosolutions, SysArris, CytoGenomics and Molecular Connec- Segment grows at 5% Domestic market contributes 68% of BioInformatics revenue tions. These companies have come out with products that cater mainly to the needs of the pharmaceutical and biotechnology companies. Most of these companies are small and medium enterprises based at locations such as Bangalore, Hyderabad, Pune. 44 BIOSPECTRUM June 2010 biospectrumindia.com A CyberMedia Publication